Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tong Ren Tang Chinese Medicine Co has a current ratio of 19.65. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
FRA:TQR's Current Ratio is ranked better than 97.6% of 999
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:TQR: 19.65
Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Beijing Tong Ren Tang Chinese Medicine Co Current Ratio Related Terms
Beijing Tong Ren Tang Chinese Medicine Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tong Ren Tang Chinese Medicine Co Current Ratio Chart
Beijing Tong Ren Tang Chinese Medicine Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tong Ren Tang Chinese Medicine Co Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) has a Current Ratio of 19.65 as of Dec. 2025. This is 26% above median its historical median of 15.65. Over the past decade, Beijing Tong Ren Tang Chinese Medicine Co's Current Ratio has ranged from 8.61 to 19.65. According to the industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #24 out of 999 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Beijing Tong Ren Tang Chinese Medicine Co's Current Ratio too high?
Beijing Tong Ren Tang Chinese Medicine Co's current Current Ratio of 19.65 is 26% above median its 10-year median of 15.65. Over the past 10 years, this metric has ranged from a low of 8.61 to a high of 19.65. The Drug Manufacturers industry median Current Ratio is 2.00. Beijing Tong Ren Tang Chinese Medicine Co's value of 19.65 is 882.5% above this industry median. Based on the distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #24 out of 999 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tong Ren Tang Chinese Medicine Co has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tong Ren Tang Chinese Medicine Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #24 out of 999 companies for Current Ratio. This places Beijing Tong Ren Tang Chinese Medicine Co in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Beijing Tong Ren Tang Chinese Medicine Co's value of 19.65 is 882.5% above this benchmark. Historically, Beijing Tong Ren Tang Chinese Medicine Co's own Current Ratio has ranged from 8.61 to 19.65 over the past decade. While the company's 10-year median is 15.65 vs. the industry median of 2.00, Beijing Tong Ren Tang Chinese Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tong Ren Tang Chinese Medicine Co's current Current Ratio of 19.65 is 882.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tong Ren Tang Chinese Medicine Co's current Current Ratio is 19.65, which is 26% above median its own 10-year median of 15.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tong Ren Tang Chinese Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.05, compared to a current price of €0.73 — trading 30.5% below its estimated fair value. The current Current Ratio is 19.65, which is 26% above median its 10-year median of 15.65 and 882.5% above the Drug Manufacturers industry median of 2.00. Beijing Tong Ren Tang Chinese Medicine Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR), the current Current Ratio is 19.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co stock appears to be undervalued.
The current stock price of €0.73 is trading 30.5% below its estimated GF Value™ of €1.05.
GuruFocus considers Beijing Tong Ren Tang Chinese Medicine Co to be Significantly Undervalued.
Key valuation signals for FRA:TQR:
Current Ratio: 19.65 (26% above median its 10-year median of 15.65)
GF Value™: €1.05 vs. price of €0.73 (30.5% below fair value)
Industry Position: 882.5% above the Drug Manufacturers median (#24 of 999)
No single metric tells the full story. See the FRA:TQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tong Ren Tang Chinese Medicine Co Business Description
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products; Chinese Mainland (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Chinese Mainland and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd; and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.
72GF Score
Get the complete analysis for FRA:TQR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TQR has been successfully added to your 
